BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HBI-2376 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HBI-2376\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05163028-2508@assetmemo.bio
DTSTAMP:20261121T005728Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HBI-2376: Phase 1 readout est. (NCT05163028)
DESCRIPTION:HBI-2376\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Dose
  Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harborin
 g KRAS of EGFR Mutations\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/hbi-2376#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05163028
URL:https://assetmemo.bio/drug/hbi-2376#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
